000			06133nam a22004455i 4500
999			_c128010 _d128010 _x1
001			128010
003			ES-MaUEC
005			20230102114329.0
006			a||||fo|||| 00| 0
007			cr nn nnnaamaa
008			200908s2020 gw | s |||| 0|eng d
020			_a9783030491277
024	7		_a10.1007/978-3-030-49127-7 _2doi
040			_aES-MaUEC _bspa _cES-MaUEC _dES-MaUEC
050		4	_aRD120.7 _b2020 EB
245	0	0	_aClinical Xenotransplantation : _bPathways and Progress in the Transplantation of Organs and Tissues Between Species _cedited by David K. C. Cooper, Guerard Byrne
250			_aFirst edition
264		1	_aCham, Switzerland _bSpringer International Publishing _c2020
300			_a1 recurso en línea (XXIX, 306 páginas) _b82 ilustraciones, 59 ilustraciones a color
336			_2rdacontent _aTexto _btxt
337			_2rdamedia _aelectrónico _bc
338			_2rdacarrier _arecurso electrónico _bcr
347			_aarchivo de texto _bPDF
490	0		_aMedicine (SpringerNature-11650)
490	0		_aMedicine (R0) (SpringerNature-43714)
505	0		_aClinical and Experimental Xenotransplantation: Background -- 1. A brief history of clinical cross-species organ xenotransplantation -- 2. The pathobiology of pig-to-primate xenotransplantation: a historical review -- 3. Is sensitization to pig antigens detrimental to subsequent allotransplantation? -- 4. Sensitization to human leukocyte antigens and xenotransplantation? -- Pig Kidney and Heart Xenotransplantation in Nonhuman Primates - the Present Position -- 5. Kidney xenotransplantation in nonhuman primates -- 6. Cardiac xenotransplantation in nonhuman primates -- Organ-source Pig Genetic Engineering and Regulation -- 7. Gene-edited pigs for xenotransplantation -- 8. Addressing regulatory requirements for the organ-source pig - a pragmatic approach to facility design and pathogen prevention -- Antibody-Mediated Allotransplant Rejection: Lessons for Xenotransplantation -- 9. Antibody-mediated graft rejection in nonhuman primate models: comparison of sensitized allotransplant and xenotransplant rejection -- 10. Management of anti-HLA antibodies and acute antibody-mediated rejection -- 11. Evolving approaches to treatment of allosensitization and antibody-mediated rejection -- 12. Lessons from ABO-incompatible cardiac allotransplantation in the newborn -- Patient Evaluation and Selection for First Clinical Trials of Kidney or Heart Xenotransplantation -- 13. Defining an "acceptable risk threshold" - who should be the first kidney xenotransplant recipient? -- 14. Selection of patients for initial clinical trials of kidney xenotransplantation -- 15. Selection of patients for initial clinical trials of cardiac xenotransplantation -- 16. Selection of pediatric patients for initial clinical trials of cardiac xenotransplantation -- 17. Infection in xenotransplantation: organ-source health and patient safety -- 18. Histocompatibility testing for xenotransplantation -- Regulatory, Economic, and Social Aspects of Clinical Trials of Xenotransplantation -- 19. Xenotransplantation; the FDA perspective -- 20. Xenotransplantation: a payer's perspective -- 21. Public perceptions towards clinical trials of organ xenotransplantation -- Summation -- 22. What did the workshop achieve?
520	3		_aThis title provides an illuminating examination of the current state of xenotransplantation - grafting or transplanting organs or tissues between members of different species - and how it might move forward into the clinic. To be sure, this is a critical topic, as a major problem that remains worldwide is an inadequate supply of organs from deceased human donors, severely limiting the number of organ transplants that can be performed each year. Based on presentations given at a major conference on xenotransplantation, this title includes important views from many leading experts who were invited to present their data and opinions on how xenotransplantation can advance into the clinic. Attention was concentrated on pig kidney and heart transplantation as it is in regard to these organs that most progress has been made. Collectively, these chapters effectively highlight the many advantages of xenotransplantation to patients with end-stage organ failure, thereby encouraging the mapping of a concrete pathway to clinical xenotransplantation. The book is organized across 22 chapters, beginning with background information on clinical and experimental xenotransplantation. Following this are discussions addressing how pigs can be genetically engineered for their organs to be resistant to the human immune response through deletion of pig xenoantigens, and the insertion of 'protective' human transgenes. Subsequent chapters analyze complications that arise in practice, comparing allotransplant and xenotransplant rejection. The selection of the ideal patients for the first clinical trials is discussed. Finally, the book concludes with an analysis on the regulatory, economic, and social aspects of this research, including FDA perspectives and the sensitive, psychosocial factors regarding allotransplantation and xenotransplantation. A major and timely addition to the literature, Clinical Xenotransplantation will be of great interest to all researchers, physicians, and academics from other disciplines with an interest in xenotransplantation.
988			_aSpringer_Medicine_2020
650		7	_aTrasplante de órganos _2embne _9140365
650		7	_aInjerto de tejidos _2embne _9676876
650		7	_aHepatología _2embne _9143270
700	1		_aCooper, David K. C _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt
700	1		_aByrne, Guerard _eeditor literario _4edt _4http://id.loc.gov/vocabulary/relators/edt
776	0	8	_iPrinted edition: _z9783030491260
776	0	8	_iPrinted edition: _z9783030491284
776	0	8	_iPrinted edition: _z9783030491291
856	4	0	_uhttps://go.openathens.net/redirector/universidadeuropea.es?url=https://doi.org/10.1007/978-3-030-49127-7 _zAcceso a este recurso digital (usuarios Universidad Europea de Madrid)
942			_2lcc _cLE
998			_dz _b01/2021 _eo _zSI